EP0763022A1 - Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques - Google Patents

Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques

Info

Publication number
EP0763022A1
EP0763022A1 EP95921759A EP95921759A EP0763022A1 EP 0763022 A1 EP0763022 A1 EP 0763022A1 EP 95921759 A EP95921759 A EP 95921759A EP 95921759 A EP95921759 A EP 95921759A EP 0763022 A1 EP0763022 A1 EP 0763022A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
group
compounds
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95921759A
Other languages
German (de)
English (en)
Inventor
Thomas Henry SmithKline Beecham Pharm. BROWN
David Gwyn SmithKline Beecham Pharm. COPPER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0763022A1 publication Critical patent/EP0763022A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to cyclic secondary amine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. .
  • WO93/15052 describe various tertiary nitrogen-containing heterocyclic compounds, which compounds are said to have activity as calcium blocking agents. Corresponding secondary amines are described as potential intermediates. In our co-pending International Application No. WO94/13291 (PCT EP93/03473) we describe various cyclic secondary amine derivatives as calcium channel antagonists. We have now found that certain of these compounds are particularly advantageous as calcium channel antagonists.
  • the present invention therefore provides, in a first aspect, a compound of formula (I):
  • X is a bond, O, CH 2 , CO or OCH and Hal is fluoro or chloro; or a pharmaceutically acceptable salt thereof as a therapeutic agent.
  • W preferably represents (CH >4 or (CH 2 )5.
  • the group -(CH2) n A(CH2) m Ar may be substituted on any carbon atom in the ring.
  • the substituent is preferably ⁇ to the ring nitrogen atom.
  • the values of n, m and A should be chosen such that the chain (CH 2 ) n A(CH ) m contains at least one atom.
  • the length of the chain -(CH 2 ) n A(CH 2 ) m is from 2 to 6 atoms.
  • Preferred values for n and m depend on the group A. Thus for example when A is oxygen the sum of n+m is from 1 to 5; for example n may be 1 or 2 and m may be zero.
  • A is preferably oxygen or a bond.
  • Particularly preferred compounds of formula (I) are those wherein W is (CH 2 )5 and the substituent -(CH 2 ) n A(CH 2 ) m Ar is oc to the ring nitrogen atom.
  • A is oxygen, n is 1 or 2 and m is zero.
  • X is O or CO.
  • Hal is in the 3- or 4-position relative to the X group, particularly preferably the 4-position. Most preferably Hal is fluoro.
  • Ci. ⁇ alkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched.
  • a Ci. ⁇ alkyl group may be for example methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as iso- propyl, tert-butyl or sec-pentyl.
  • a salt of a compound (I) should be pharmaceutically acceptable.
  • pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Other non- pharmaceutically acceptable salts, such as oxalates may be used for example in the isolation of final products and are included within the scope of this invention.
  • the compounds according to the present invention can be prepared by processes analogous to those known in the art, for example the general methods described in WO92/02501 , WO92/02502, WO92/22527 and WO93/15052.
  • the present invention provides a process for the preparation of a compound of formula (I) which process comprises:
  • R 4a is hydrogen or an N-protecting group, and W, n, m, and Ar are as described above.
  • L(CH 2 ) m Ar can take place under conditions which depend on the nature of the group L and the value of m.
  • L is preferably fluoro, such that the compound of formula (II) is reacted with a compound F-Ar.
  • the reaction is preferably effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as DMSO or dimethylformamide.
  • L is halogen or a sulphonic acid residue such as a tosylate or mesylate and m is other than zero
  • the reaction is carried out under standard conditions in a solvent, optionally in the presence of a base.
  • HAl(CH 2 ) m Ar can take place under conditions which depend on the nature of L and A* .
  • L is hydroxy
  • m is 0
  • A is oxygen or sulphur the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine.
  • the leaving group l may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy.
  • the reaction may be effected in the presence or absence of solvent and at temperature in the range 0 to
  • a compound of formula (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
  • a compound of formula (IV) can be prepared (for example as described below) and reduced in a 'one-pot' reaction, without isolation of compound (IV) itself.
  • reaction between a compound of formula (V) and a compound of formula ⁇ l Ar in process (d) can take place under standard conditions known to those skilled in the art for the formation of carbon-carbon bonds.
  • Reduction of a compound of formula (VI) according to process (e) may be effected for example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg. ethanol.
  • a noble metal catalyst such as platinum, palladium or platinum oxide
  • Process (f) may be effected using a Wadsworth-Emmons reagent of the formula Ar(CH 2 ) m+ ⁇ P(O)(OAlk) 2 , such as a diethylphosphonate, or a Wittig reagent of the formula Ar(CH ) m+ ⁇ PPh3X" (where X" is an anion) which compounds are available commercially or can be prepared by known methods.
  • the reaction may be carried out in a solvent such as tetrahydrofuran optionally containing a crown ether such as 15-crown-5 or 18-crown-6, and in the presence of a strong base such as sodium hydride, or potassium tert-butoxide.
  • Interconversion reactions according to process (g) may be effected by methods well known in the art.
  • Protecting groups R 4 include lower alkyl groups such as methyl; aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl; and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl.
  • a protecting group R 4a is preferably alkyl e.g. methyl or aralkyl e.g. benzyl. Such groups may be removed by methods which are well known in the art.
  • alkyl group such as methyl may be removed by treatment with a haloalkyl haloformate such a 1-chloromethylchloroformate, aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis.
  • a protecting group R 4 or R 4a present in any of the above compounds (II) to (VII) as well as compounds (Vffl) below should be chosen such that it will not be cleaved by or participate in any of the reactions that the particular compound is intended to undergo, and furthermore such that its removal will not disturb any other groups or moieties present in the molecule. Such factors can be readily ascertained by those skilled in the art, to whom appropriate protecting groups will thus be readily apparent.
  • acyl group may be introduced by reaction with an appropriate acid derivative such as an acid chloride or anhydride, or an activated ester, e.g. an alkyldicarbonate such as di-tert-butyldicarbonate or a haloformate such as ethylchloroformate.
  • an appropriate acid derivative such as an acid chloride or anhydride
  • an activated ester e.g. an alkyldicarbonate such as di-tert-butyldicarbonate or a haloformate such as ethylchloroformate.
  • the compounds of formula (II) in which A 1 is oxygen can be prepared by reduction of a compound of formula (VIII):
  • R 4 and n are as hereinbefore described.
  • R 4 should be a group such as alkyl, which is not cleaved by reductive conditions.
  • C(O)N(R 1 )(CH 2 ) m Ar may be prepared for example by reaction of a corresponding compound wherein R-5 represents -(CH 2 ) n . ⁇ CO 2 H or an activated derivative thereof such as an acid halide, ester or anhydride, with an amine of formula HN(Rl)(CH 2 ) m Ar. It will be appreciated that when the acid itself is employed, reaction with the amine should be effected in the presence of a coupling agent.
  • the carboxylic acid may itself be prepared for example by oxidation of the corresponding alcohol, ie. a compound of formula (II) wherein A 1 is oxygen.
  • Compounds of formula (V) may be prepared in analogous manner to compounds of formula (HI); where necessary the chain length may be increased using methods well known in the art.
  • a compound of formula (VI) may be prepared using the general methods described in processes (a) to (d) above.
  • Compounds of formula (VII) may be prepared by conventional methods, for example the oxidation of a compound of formula (II) wherein A 1 is oxygen, or conversion of the corresponding ester, e.g. by reaction with thionyl chloride and N,O-dimethylhydroxylamine hydrochloride, to give the N-methyl-N-methoxy- carboxamide, which can be reduced to the aldehyde using diisobutylaluminium hydride.
  • Compounds of formula (VII) wherein n is i may be prepared from the corresponding compound wherein n is zero by various methods.
  • the aldehyde wherein n is zero may be treated with (methoxymethyl) triphenylphosphonium chloride and potassium t-butoxide, followed by a strong acid. e.g. concentrated sulphuric acid, resulting in the aldehyde wherein n is 1.
  • a strong acid e.g. concentrated sulphuric acid
  • the aldehyde may be converted to the corresponding cyanomethyl derivative as described in EPA 363085 followed by acid hydrolysis, conversion to the N-methyl-N-methoxycarboxamide and reduction. These procedures may also be used to form higher homologues.
  • a compound of formula (I) When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
  • Suitable resolving agents include optically active acids such as R-(-)- or S-(+)-mandelic acid or.
  • a mixture of diastereomeric amides may be prepared by reacting a mixture of enantiomers of formula (I) with an optically active reagent such as S(+)- ⁇ - methoxyphenylacetic acid, in the form of a reactive derivative such as an acid chloride.
  • the mixture of amides may be separated by conventional methods and then converted into the resolved amines by hydrolysis.
  • An ischaemic event such as stroke results in disruption of the blood supply to the brain, depriving it of essential oxygen.
  • a cascade of biochemical reactions ensues, a consequence of which is to permit the influx of calcium ions into the brain cells (neurons) via so-called Voltage Operated Calcium Channels (VOCCs) causing cell death. It is believed that agents which inhibit such calcium influx will minimise cell death and hence increase the potential for recovery.
  • VOCCs Voltage Operated Calcium Channels
  • Compounds of formula (I) have been found to exhibit high calcium influx blocking activity for example in neurons.
  • the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans.
  • the compounds are expected to be of use in the treatment of ischaemia including for example stroke, anoxia, and traumatic head injury. They may also be of use in the treatment of migraine, visceral pain, epilepsy, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal.
  • a method of treatment of conditions or diseases related to e.g.
  • the present invention provides a method of treatment of ischaemia including for example stroke, anoxia or traumatic head injury which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method of treatment of migraine, visceral pain, epilepsy, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease, and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition or disease related to the accumulation of calcium in the brain cells of a mammal.
  • Compounds of the present invention will preferably be of use in the treatment of ischaemic stroke.
  • the compounds of the present invention are usually administered in a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
  • the compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion.
  • Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • Both liquid and solid compositions may contain other excipients known in the pharmaceutical art, such as a cyclodextrin or a solubilising agent such as Cremophor.
  • composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400mg per day.
  • the total daily dosage by oral administration will be in the range 1 to 2000 mg and the total daily dosage by parenteral administration will be in the range 0.1 to 400 mg.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination or concurrently with one or more other therapeutic agents, for example a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator, an excitatory amino acid antagonist such as an NMDA antagonists; a free radical inhibitor; or a calpain inhibitor.
  • Ca ⁇ + current can be measured in vitro using cell preparations of sensory neurons from dorsal root ganglia as described in WO92/02501 and WO92/02502, or sensory neurons from superior cervical ganglia as described in WO95/04027.
  • Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
  • Solvent Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.
  • Diluent e.g. Microcrystalline cellulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethy .cellulose
  • Disintegrant e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate.
  • Suspending agent e.g. Xanthan gum, microcrystalline cellulose
  • Solubiliser e.g. hydroxypropyl ⁇ cyclodextrin
  • Diluent e.g. sorbitol solution, typically water
  • Preservative e.g. sodium benzoate
  • Buffer e.g. citrate
  • Co-solvent e.g. alcohol, propylene glycol, polyethylene glycol
  • N-BOC-2- ⁇ iperidine ethanol (2.29g, lOmM), triphenyl phosphine (2.60g, lOmM) and 4- chloro-4'-hydroxybenzophenone (2.35g, lOmM) were dissolved with stirring under argon in dry dichloromethane (50ml).
  • the mixture was cooled in an ice-bath and a solution of diethylazodicarboxylate (1.75g, lOmM) in dry CH 2 C1 2 (20ml) was added dropwise.
  • the clear brown solution produced was allowed to slowly reach room temperature and stood under argon for sixty hours.
  • the faster eluting diastereomer (2.14g) was dissolved in dry tetrahydrofuran (150ml) and treated with potassium tert-butoxide (20g) and water (0.335ml). The mixture was stirred vigorously for 45 minutes. After filtering off the solid material the mixture was concentrated in vacua and the residue partitioned between diethyl ether and water. The organic fraction was washed (H2O, brine), dried (Na2SO4) and evaporated to dryness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de la formule (I) ainsi que leurs sels, dans laquelle W représente -(CH2)4, (CH2)5, -(CH2)2O(CH2)2 ou -(CH2)2S(CH2)2, n vaut 0 à 6, m vaut 0 à 3, A représente une liaison, -CH=CH-, -C C-, oxygène, soufre ou NR1, R1 représente hydrogène, alcoyle C¿1-8? ou phényle alcoyle C1-4, et Ar représente un groupe (a) dans lequel X représente une liaison, O, CH2, CO ou OCH2 et Hal représente fluoro ou chloro. Ces composés sont des antagonistes des canaux calciques possédant une activité dans les neurones et ils sont utiles dans le traitement d'états pathologiques tels que l'attaque ischémique.
EP95921759A 1994-06-02 1995-05-24 Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques Withdrawn EP0763022A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9411045 1994-06-02
GB9411045A GB9411045D0 (en) 1994-06-02 1994-06-02 Compounds and use
PCT/EP1995/002003 WO1995033723A1 (fr) 1994-06-02 1995-05-24 Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques

Publications (1)

Publication Number Publication Date
EP0763022A1 true EP0763022A1 (fr) 1997-03-19

Family

ID=10756077

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95921759A Withdrawn EP0763022A1 (fr) 1994-06-02 1995-05-24 Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques

Country Status (4)

Country Link
EP (1) EP0763022A1 (fr)
JP (1) JPH10500698A (fr)
GB (1) GB9411045D0 (fr)
WO (1) WO1995033723A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843983A (en) * 1996-02-15 1998-12-01 Sankyo Company, Limited Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use
AU4455397A (en) * 1996-08-23 1998-03-06 Neurosearch A/S Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
WO1999043658A1 (fr) 1998-02-27 1999-09-02 Warner-Lambert Company Agents d'aniline heterocyclique substituee bloquant les canaux de calcium
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
WO2000021550A2 (fr) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methodes et compositions de traitement des maladies neurodegeneratives
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
EP1707203A1 (fr) * 2005-04-01 2006-10-04 Bioprojet Utilization des allkylamines sans imidazoles comme ligandes du recepteur histamine H3 pour le traitement de la maladie de Parkinson, de l'apnee obstructive du sommeil, de la demence vasculaire et de la demence avec corps de Lewy
UA101943C2 (ru) * 2005-09-21 2013-05-27 Декод Дженетикс Ехф Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
MX9100517A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
AU3364493A (en) * 1992-01-28 1993-09-01 Smithkline Beecham Plc Compounds as calcium channel antagonists
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9533723A1 *

Also Published As

Publication number Publication date
JPH10500698A (ja) 1998-01-20
WO1995033723A1 (fr) 1995-12-14
GB9411045D0 (en) 1994-07-20

Similar Documents

Publication Publication Date Title
US5935951A (en) 1-acyl-4-aliphatylaminopiperidine compounds
US7951821B2 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
JP3022951B2 (ja) アロイル−ピペリジン誘導体
US4943578A (en) Piperazine compounds
EP0374801B1 (fr) Acides azahétérocycliques N-substitués
MXPA02008244A (es) Compuestos novedosos.
IL174942A (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl]arylamides, pharmaceutical compositions comprising them and their use in the preparation of medicaments
KR20040103973A (ko) Ｎ-[페닐(피페리딘-2-일)메틸]벤즈아미드의 유도체, 그의제조 방법 및 치료법에서의 그의 용도
US20030176693A1 (en) Diphenylalkylamine derivatives useful as opioid receptor agonists
WO2001087838A1 (fr) Derives de cyclohexyle et leur utilisation comme agents therapeutiques
AU2001256509A1 (en) Cyclohexane derivatives and their use as therapeutic agents
JPH02138254A (ja) 複素環誘導体
EP0674514A1 (fr) Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle
US20050148583A1 (en) Phenoxyalkylamine derivatives useful as opioid delta receptor ligands
KR930002728B1 (ko) 피페리딘 유도체
WO1995033723A1 (fr) Piperidines, pyrrolidines, morpholines et thiomorpholines a substitution phenoxyalcoyle, en tant qu'antagonistes des canaux a calciques
US6218390B1 (en) Morpholinone and morpholine derivatives and uses thereof
FI106957B (fi) Menetelmä lääkeaineina käyttökelpoisten alfa-[(2-aminoalkoksi)fenyyli]-omega-aryylialkaanien valmistamiseksi
WO1995033722A1 (fr) Piperidines, pyrrolidines, morpholines et tiopmorpholines a substitution phenoxyalcoyle en tant qu'antagonistes des canaux calciques
EP0724577A1 (fr) Amines heterocycliques pour le traitement des acces ischemiques
US5214148A (en) Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
WO1995024390A1 (fr) Nouvelles piperidines substituees par phenyl(-alkyl/alkoxy)-1-aminoalkyle et pyrolidines utilisees comme antagonistes des canaux calciques
SI9300217A (sl) Farmacevtiki, ki vsebujejo ariloksialkilamino in ariltioalkilamino derivate
JPH09504014A (ja) カルシウムチャネル拮抗薬としてのアミン誘導体類
EP0158283A2 (fr) 1-Aminoalkylamino-4-aryloxypipéridines, procédé pour leur préparation, leurs intermédiaires et leur utilisation comme médicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971202